The National Medical Products Administration of China has granted conditional approval for a new cancer treatment aimed at patients with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive form of blood cancer with limited treatment options.
As reported by
China Daily, a partner of TV BRICS, the authorisation applies to adults who have previously undergone at least one systemic therapy.
The drug is the country’s first domestically developed EZH2 inhibitor. EZH2 is an enzyme linked to cancer cell growth, and medicines that target it are regarded as a promising direction in oncology.
The developers emphasised that the treatment is a selective oral therapy intended to offer a new option for patients with limited alternatives.
Photo: zhudifeng /
iStock
Самые
актуальные новости стран БРИКС https://tvbrics.com